Carbamates as potent calcitonin gene-related peptide antagonists with improved solution stability

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 13, 2009, Pages 3555-3558

  Degnan, Andrew P ^a   Conway, Charles M ^a   Dalterio, Richard A ^a   Macci, Robert ^a   Mercer, Stephen E ^a   Schartman, Richard ^a   Xu, Cen ^a   Dubowchik, Gene M ^a   Macor, John E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Calcitonin gene related peptide; Carbamates; CGRP; Solution stability

Indexed keywords

BMS 694153; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CARBAMIC ACID DERIVATIVE; UNCLASSIFIED DRUG; URETHANAMIDE DERIVATIVE;

AQUEOUS SOLUTION; ARTICLE; DRUG DEGRADATION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STABILITY; IC 50; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

CARBAMATES; DRUG STABILITY; HUMANS; INDAZOLES; MIGRAINE DISORDERS; QUINAZOLINONES; QUINOLONES; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;

EID: 66349123811     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.150     Document Type: Article

References (15)

1. Beers, M. H., Porter, R. S., Jones, T. V., Kaplan, J. L., Berkwitz, M.; Eds.; "Migraine" in Merck Manual, 18th ed.; Merck Research Laboratories: Whitehouse Station, NJ, 2006; pp 1847.
2. Edvinsson L., Uddman E., Wackenfors A., Davenport A., Longmore J., and Malmsjö M. Clin. Sci. 109 (2005) 335
3. Goadsby P.J., Lipton R.B., and Ferrari M.D. N. Eng. J. Med. 346 (2002) 257
4. Goadsby P.J. Drugs 65 (2005) 2557
5. Edvinsson L. Cephalalgia 24 (2004) 611
6. Williamson D.J., and Hargreaves R. J. Microsc. Res. Tech. 53 (2001) 167
7. Goadsby P.J., Edvinsson L., and Ekman R. Ann. Neurol. 28 (1990) 183
8. Goadsby P.J., and Edvinsson L. Ann. Neurol. 33 (1993) 48
9. Lassen L.H., Haderslev P.A., Jacobsen V.B., Iversen H.K., Sperling B., and Olesen J. Cephalalgia 22 (2002) 54
10. Olesen J., Diener H.C., Husstedt I.W., Goadsby P.J., Hall D., Meier U., Pollentier S., and Lesko L.M. N. Eng. J. Med. 350 (2004) 1104
11. Oral CGRP anatagonist medicinal chemistry efforts have been described in:. Bell I.M., Bednar R.A., Fay J.F., Gallicchio S.N., Hochman J.H., McMasters D.R., Miller-Stein C., Moore E.L., Mosser S.D., Pudvah N.T., Quigley A.G., Salvatore C.A., Stump C.A., Theberge C.R., Wong B.K., Zartman C.B., Zhang X.-F., Kane S.A., Graham S.L., Vacca J.P., and Williams T.M. Bioorg. Med. Chem. Lett. 16 (2006) 6165
12. Williams T.M., Stump C.A., Nguyen D.N., Quigley A.G., Bell I.M., Gallicchio S.N., Zartman C.B., Wan B.-L., Della Penna K., Kunapuli P., Kane S.A., Koblan K.S., Mosser S.D., Rutledge R.Z., Salvatore C., Fay J.F., Vacca J.P., and Graham S.L. Bioorg. Med. Chem. Lett. 16 (2006) 2595
13. Degnan A.P., Chaturvedula P.V., Conway C.M., Cook D.A., Davis C.D., Denton R., Han X., Macci R., Mathias N.R., Moench P., Pin S.S., Ren S.X., Schartman R., Signor L.J., Thalody G., Widmann K.A., Xu C., Macor J.E., and Dubowchik G.M. J. Med. Chem. 51 (2008) 4858
14. Luo G., Chen L., and Dubowchik G. J. Org. Chem. 71 (2006) 5392
15. Burk M.J., Kalberg C.S., and Pizzano A. J. Am. Chem. Soc. 120 (1998) 4345